---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-002113"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:14:23.940857+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Virios reports FY2023 net loss $5.3M, down 57% YoY; FDA aligns on Long-COVID endpoint for IMC-2

## Summary
- Net loss for FY2023 $5.3M ($0.28/share), down from $12.2M ($1.11/share) in FY2022.
- R&D expenses $1.7M in FY2023 vs $8.1M in FY2022, driven by lower clinical trial costs.
- Cash at Dec 31, 2023: $3.3M; expected to fund operations into Q4 2024.
- FDA agreed to use fatigue as primary endpoint for IMC-2 Phase 2 in Long-COVID; initiation targeted H2 2024, pending funding.
- Placebo-controlled data on valacyclovir/celecoxib for Long-COVID from Bateman Horne Center expected summer 2024.

## SEC filing metadata
- accession: 0001558370-24-002113
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024002113/0001558370-24-002113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024002113/tmb-20240229x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-002113
- JSON: https://secwatch.observer/filing/0001558370-24-002113.json
- Plain text: https://secwatch.observer/filing/0001558370-24-002113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.